GSK Raises 2025 Profit Forecast as HIV and Cancer Drugs Drive Growth
GSK boosts annual profit forecast to 12% growth as specialty medicines outperform. CEO Emma Walmsley's final report shows strong Q3 results despite US vaccine challenges.
GSK boosts annual profit forecast to 12% growth as specialty medicines outperform. CEO Emma Walmsley's final report shows strong Q3 results despite US vaccine challenges.
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
AstraZeneca joins Pfizer in a landmark agreement with the Trump administration, promising "most-favored nation" drug prices, direct-to-consumer sales up to 80% off list price, and a massive investment in U.S. manufacturing in exchange for a three-year tariff exemption.
Pfizer avoided US tariffs by offering big drug discounts (TrumpRx). This deal is a blueprint. European drug stocks (AstraZeneca, Roche) surged hoping for similar agreements to protect their crucial sales from Trump's 100% import tax threat.
President Trump is hitting imports with massive new tariffs starting October 1st, targeting branded drugs (100%), heavy trucks (25%), and furniture.
Mineralys shares surged 86% after AstraZeneca announced positive Phase 3 results for its similar blood pressure drug, Baxdrostat. "The results seem slightly worse than Mineralys' Lorundrostat," according to Jefferies. This could lead to business deals for MLYS, which may be "best in class".